Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets Thrombin. Ichorcumab binds to exosite 1 on thrombin and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 kappa, Isotype Control [1].
In Vitro, Ichorcumab (JNJ‐9375) prolongs clotting times by binding to exosite 1 on thrombin and preventing its interaction with fibrinogen and other substrates such as factors V and VIII and protease activated receptor 1. Because Ichorcumab does not affect the catalytic activity of thrombin, Ichorcumab may produce less bleeding than anticoagulants that block the active site of thrombin or factor Xa[1].
References:
[1]. Weitz JI, et al. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 Dec;17(12):2081-2088.
In Vitro, Ichorcumab (JNJ‐9375) prolongs clotting times by binding to exosite 1 on thrombin and preventing its interaction with fibrinogen and other substrates such as factors V and VIII and protease activated receptor 1. Because Ichorcumab does not affect the catalytic activity of thrombin, Ichorcumab may produce less bleeding than anticoagulants that block the active site of thrombin or factor Xa[1].
References:
[1]. Weitz JI, et al. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 Dec;17(12):2081-2088.